Market Report Source

Overview

Antihormonal therapies are a class of cancer therapeutics that generated branded drug sales of $5.8 billion in the seven major pharmaceutical markets in 2007. However, the relative maturity of the market means that it is has become a highly genericized therapeutic class. Even still, the lack of innovation within this saturated market helps many leading brands retain their success.

Scope of this report:

• Analysis of the performance of each of the antihormonal therapy cancer brands in the seven major markets, forecast to 2017
• Analysis and segmentation of the market at various levels including drug class, indication, company and sales growth rate
• Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
• Quantification of the market size of the antihormonal therapy cancer brands in the seven major pharmaceutical markets with a rest of world snapshot

Research and analysis highlights:

The antihormonal therapy cancer brands market was worth $5.8 billion in 2007and is forecast to decline in sales to $5.2 billion by 2017. Factors limiting market growth include patent expirations, the increasing entry of generic competitors onto the market and the interchangeable nature of some brands within each class.

As a class, the aromatase inhibitor brands achieved higher sales than the luteinizing hormone-releasing hormone analog, anti-androgen or anti-estrogen brands in 2007, achieving $2.4 billion in the seven major pharmaceutical markets. The success enjoyed by the aromatase inhibitors can be attributed, in part, to their favorable side effect profile.

Thirteen differently sized pharmaceutical companies are involved in the development of currently approved antihormonal therapy cancer brands. AstraZeneca leads market, with five out of the 11 brands and includes the leading aromatase inhibitor brand Arimidex.

Key reasons to read this report:

• Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2007 to 2017
• Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
• Benchmark the antihormonal therapy cancer brands against their generic products and align their 7MM performance with a rest of world snapshot

Table of Contents

CHAPTER 1 EXECUTIVE SUMMARY
Strategic scoping and focus

Datamonitor insight into the antihormonal therapy cancer brands market
Related reports
Upcoming reports

CHAPTER 2 MARKET DEFINITION
Definition of the cancer market
Antihormonal therapies by ATC class
L2A3 – Luteinizing hormone-releasing hormone analogs
L2B1 – Anti-estrogens
L2B2 – Anti-androgens
L2B3 – Aromatase inhibitors

CHAPTER 3 MARKET OVERVIEW AND FORECASTS
Seven major markets
Current market assessment
Sales by class
Sales by brand
Sales by country
Future market assessment
Sales by class
Sales by brand
Sales by country
Opportunities and threats

US
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

Japan
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

5EU
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

France
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

Germany
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

Italy
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

Spain
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

UK
Current market assessment
Sales by class
Sales by brand
Future market assessment
Sales by class
Sales by brand

Rest of World snapshot
Current market assessment

• Global antihormonals market
• Global LHRH analog market
• Global anti-estrogens market
• Global anti-androgens market
• Global aromatase inhibitors market

CHAPTER 4 BRAND DYNAMICS
Brand analysis by class
Aromatase inhibitors represent the largest class of antihormonal therapy brands
Brand analysis by indication
82% of antihormonal brands are approved for breast cancer
Brand analysis by company
AstraZeneca markets almost half of the antihormonal therapy cancer brands
AstraZeneca
Novartis
Brand analysis by event
Faslodex will experience the greatest number of forecast events across the seven major
markets
Brand analysis by sales growth
Anti-estrogen brands are the only antihormonal class showing positive sales growth for
2007-2017
Brand versus generic market snapshot
Seven major markets
Branded products often preferred, despite the availability of cheaper generics

• US
• Japan
• 5EU
• France
• Germany
• Italy
• Spain
• UK

CHAPTER 5 BRAND PROFILES AND FORECASTS

Afema (fadrozole; Novartis)
Brand profile
Brand forecast events*
Brand forecast to 2017

Arimidex (anastrozole; AstraZeneca)
Brand profile
Brand forecast events
Brand forecast to 2017
Arimidex set to maintain its blockbuster and gold-standard status despite patent expiry

Aromasin (exemestane; Pfizer)
Brand profile
Brand forecast events
Brand forecast to 2017
Aromasin fails to match its competitors in-class, although its alternative mechanism of action presents some opportunity

Casodex (bicalutamide; AstraZeneca)
Brand profile
Brand forecast events
Brand forecast to 2017
Upcoming patent expiries set to hamper sales of this class-leading brand

Fareston (toremifene; Orion)
Brand profile
Brand forecast events
Brand forecast to 2017

Faslodex (fulvestrant; AstraZeneca)
Brand profile
Brand forecast events
Brand forecast to 2017

Femara (letrozole; Novartis/Chugai)
Brand profile
Brand forecast events
Brand forecast to 2017
Final results from FACE trial could indicate definitive superiority for Femara over Arimidex

Lupron (leuprorelin; Takeda/Abbott/TAP/Wyeth)
Brand profile
Brand forecast events*
Brand forecast to 2017
Lupron’s lifecycle has been extended by the launch of various formulations

Nolvadex (tamoxifen; AstraZeneca)
Brand profile
Brand forecast events*
Brand forecast to 2017
Advent of aromatase inhibitors and high generic competition continues to threaten brand sales

Suprefact (buserelin; Sanofi-Aventis)
Brand profile
Brand forecast events*
Brand forecast to 2017

Zoladex (goserelin; AstraZeneca)
Brand profile
Brand forecast events*
Brand forecast to 2017
Despite equivalent clinical efficacy to Lupron, Zoladex remains the second best-selling LHRH analog

APPENDIX A – MARKET ASSUMPTIONS
Country-specific assumptions and events

• Effect of Medicare Modernization Act in the US
• Biennial price cuts in Japan
• Generic erosion assumptions

Data definitions, limitations and assumptions

• Standard units
• Japanese market data
• Derivation of sales forecasts and pricing trends

Forecasts
Forecast methodology

APPENDIX B
Bibliography
List of figures
Abbreviations
Report methodology
About Datamonitor

• About Datamonitor Healthcare
• Disclaimer

List of Tables
Table 1: Definition of the cancer market, 2008
Table 2: Seven major market sales of antihormonal therapy cancer brands by drug class, 2007
Table 3: Seven major market sales of antihormonal therapy cancer brands, 2007
Table 4: Individual country sales of antihormonal therapy cancer brands, 2007
Table 5: Seven major market forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 6: Seven major market forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 7: Individual country forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 8: US sales of antihormonal therapy cancer brands by drug class, 2007
Table 9: US sales of antihormonal therapy cancer brands, 2007
Table 10: US forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 11: US forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 12: Japan sales of antihormonal therapy cancer brands by drug class, 2007
Table 13: Japan sales of antihormonal therapy cancer brands, 2007
Table 14: Japan forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Table 15: Japan forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 16: 5EU sales of antihormonal therapy cancer brands by drug class, 2007
Table 17: 5EU major market sales of antihormonal therapy cancer brands, 2007
Table 18: 5EU forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 19: 5EU forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 20: France sales of antihormonal therapy cancer brands by drug class, 2007
Table 21: France sales of antihormonal therapy cancer brands, 2007
Table 22: France forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 23: France forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 24: Germany sales of antihormonal therapy cancer brands by drug class, 2007
Table 25: Germany sales of antihormonal therapy cancer brands, 2007
Table 26: Germany forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 27: Germany forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 28: Italy sales of antihormonal therapy cancer brands by drug class, 2007
Table 29: Italy sales of antihormonal therapy cancer brands, 2007
Table 30: Italy forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 31: Italy forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 32: Spain sales of antihormonal therapy cancer brands by drug class, 2007
Table 33: Spain sales of antihormonal therapy cancer brands, 2007
Table 34: Spain forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 35: Spain forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 36: UK sales of antihormonal therapy cancer brands by drug class, 2007
Table 37: UK sales of antihormonal therapy cancer brands, 2007
Table 38: UK forecast sales of antihormonal therapy cancer brands by drug class ($m), 2007-2017
Table 39: UK forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Table 40: US, Japan, 5EU and RoW total antihormonal therapy market sales, 2007
Table 41: US, Japan, 5EU and RoW total LHRH analog therapy market sales, 2007
Table 42: US, Japan, 5EU and RoW total anti-estrogen therapy market sales, 2007
Table 43: US, Japan, 5EU and RoW total anti-androgen therapy market sales, 2007
Table 44: US, Japan, 5EU and RoW total aromatase inhibitors therapy market sales, 2007
Table 45: CAGR (%) of antihormonal therapy cancer brands by drug class, 2007-2017
Table 46: CAGR (%) of antihormonal therapy cancer brands, 2007-2017
Table 47: Afema: key facts
Table 48: Afema forecast sales in the seven major markets ($m), 2007-2017
Table 49: Arimidex: key facts
Table 50: Arimidex: brand forecast events
Table 51: Arimidex forecast sales in the seven major markets ($m), 2007-2017
Table 52: Aromasin: key facts
Table 53: Aromasin: brand forecast events
Table 54: Aromasin forecast sales in the seven major markets ($m), 2007-2017
Table 55: Casodex: key facts
Table 56: Casodex: brand forecast events
Table 57: Casodex forecast sales in the seven major markets ($m), 2007-2017
Table 58: Fareston: key facts
Table 59: Fareston: brand forecast events
Table 60: Fareston forecast sales in the seven major markets ($m), 2007-2017
Table 61: Faslodex: key facts
Table 62: Faslodex: brand forecast events
Table 63: Faslodex forecast sales in the seven major markets ($m), 2007-2017
Table 64: Femara: key facts
Table 65: Femara: brand forecast events
Table 66: Femara forecast sales in the seven major markets ($m), 2007-2017
Table 67: Lupron: key facts
Table 68: Lupron forecast sales in the seven major markets ($m), 2007-2017
Table 69: Nolvadex: key facts
Table 70: Nolvadex forecast sales in the seven major markets ($m), 2007-2017
Table 71: Suprefact: key facts
Table 72: Suprefact forecast sales in the seven major markets ($m), 2007-2017
Table 73: Zoladex: key facts
Table 74: Zoladex forecast sales in the seven major markets ($m), 2007-2017
Table 75: Abbreviations used in DMHC2415 Antihormonal Therapy Cancer Brands

List of Figures
Figure 1: Seven major market sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 2: Seven major market sales and market share of antihormonal therapy cancer brands, 2007
Figure 3: Individual country sales and market share of antihormonal therapy cancer brands, 2007
Figure 4: Seven major market forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 5: Seven major market forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 6: Seven major market forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 7: Seven major market forecast sales and market share of antihormonal therapy cancer brands, 2017
Figure 8: Individual country forecast sales of antihormonal therapy cancer brands ($m), 2007-2017
Figure 9: Individual country forecast sales and market share of antihormonal therapy cancer brands, 2017
Figure 10: Summary of opportunities and threats for antihormonal therapy cancer brands in the seven major markets, 2008
Figure 11: US sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 12: US forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 13: US forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 14: US forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 15: Japan sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 16: Japan forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 17: Japan sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 18: Japan forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 19: 5EU sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 20: 5EU forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 21: 5EU forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 22: 5EU forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 23: France sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 24: France forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 25: France forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 26: France forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 27: Germany sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 28: Germany forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 29: Germany forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 30: Germany forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 31: Italy sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 32: Italy forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 33: Italy forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 34: Italy forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 35: Spain sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 36: Spain forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 37: Spain forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 38: Spain forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 39: UK sales and market share of antihormonal therapy cancer brands by drug class, 2007
Figure 40: UK forecast sales of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 41: UK forecast sales and market share of antihormonal therapy cancer brands by drug class, 2017
Figure 42: UK forecast sales of antihormonal therapy cancer brands, 2007-2017
Figure 43: US, Japan, 5EU and RoW total antihormonal therapy market sales and market share, 2007
Figure 44: US, Japan, 5EU and RoW total LHRH analog therapy market sales and market share, 2007
Figure 45: US, Japan, 5EU and RoW total anti-estrogen therapy market sales and market share, 2007
Figure 46: US, Japan, 5EU and RoW anti-androgen therapy market sales and market share, 2007
Figure 47: US, Japan, 5EU and RoW total aromatase inhibitors therapy market sales and market share, 2007
Figure 48: Number of approved antihormonal therapy cancer brands by drug class, 2008
Figure 49: Sales analysis of antihormonal brands by approved oncology indications in the seven major markets, 2008
Figure 50: Analysis of companies by number of approved antihormonal therapy cancer brands in the seven major markets, 2008
Figure 51: Analysis of antihormonal therapy cancer brands by number of forecast events, 2008-2017
Figure 52: CAGR of antihormonal therapy cancer brands by drug class, 2007-2017
Figure 53: CAGR (%) of antihormonal therapy cancer brands, 2007-2017
Figure 54: Seven major market sales of brand and generic antihormonal therapies in terms of volume and value sales by drug class, 2007
Figure 55: US sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 56: Japan sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 57: 5EU sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 58: France sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 59: Germany sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 60: Italy sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 61: Spain sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007
Figure 62: UK sales of brand and generic antihormonal therapies in terms of volume and sales by drug class, 2007